In this self-learning course, you will follow Jill, a pharmacist working in collaboration with rheumatologists for many years, and three rheumatology patients: Jackie, Jacqueline and Jack. Approved for 1.25 continuing education credits. CCCEP #1044-2023-3669-B-P.
Learning objectives:
- Discuss practical considerations regarding the treatment monitoring and follow-up of patients treated with JAK Inhibitors
- Provide tools for pharmacists to help guide patients who are prescribed targeted-synthetic therapy, including safety and efficacy considerations
- Describe the role of pharmacists in providing care to patients with rheumatoid arthritis (RA), psoriatic arthritis (PsA), and/or ankylosing spondylitis (AS) on JAK inhibitor therapy
Scientific committee:
Michael Boivin, pharmacist consultant, CME developer; Carolyn Whiskin, RPh BScPhm, NCMP, clinical pharmacist; and Dr. Caylib Durand, rheumatologist
This activity has received financial support from AbbVie Canada in the form of an educational grant.
This continuing education is free for members of CanadianHealthcareNetwork.ca. Log in and click here to take the course: